Skip to main content
Back
ABBV logo

AbbVie Inc.

Data quality: 100%
Oversold
ABBV
NYSE Healthcare Drug Manufacturers - General
$204.93
▼ $0.14 (-0.07%)
Mkt Cap: 362.35B
Day Range
$203.24 $208.62
52-Week Range
$164.39 $244.81
Volume
7,340,882
50D / 200D Avg
$223.12 / $215.25
Prev Close
$205.07

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 85.7 0.4
P/B 2.9
ROE % 15367.3 3.8
Net Margin % 6.9 3.9
Rev Growth 5Y % 2.1 10.0
D/E 0.2

Analyst Price Target

Hold
$256.15 +25.0%
Low: $223.00 High: $299.00
Forward P/E
14.1
Forward EPS
$14.57
EPS Growth (est.)
+0.0%
Est. Revenue
67 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $20.05
$19.56 – $20.40
84 B 5
FY2029 $19.55
$19.07 – $19.89
82 B 10
FY2028 $17.87
$13.13 – $21.13
78 B 12

Key Takeaways

Revenue grew 2.14% annually over 5 years — modest growth
ROE of 15367.27% indicates high profitability
Generating 17.82B in free cash flow
P/E of 85.74 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.43%
Cash machine — converts 421.58% of earnings into free cash flow

Growth

Revenue Growth (5Y)
2.14%
Revenue (1Y)8.57%
Earnings (1Y)-1.22%
FCF Growth (3Y)-10.14%

Quality

Return on Equity
15367.27%
ROIC24.18%
Net Margin6.91%
Op. Margin34.69%

Safety

Debt / Equity
N/A
Current Ratio0.67
Interest Coverage8.08

Valuation

P/E Ratio
85.74
P/B RatioN/A
EV/EBITDA20.09
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.57% Revenue Growth (3Y) 6.11%
Earnings Growth (1Y) -1.22% Earnings Growth (3Y) -6.78%
Revenue Growth (5Y) 2.14% Earnings Growth (5Y) -22.21%
Profitability
Revenue (TTM) 61.16B Net Income (TTM) 4.23B
ROE 15367.27% ROA 3.15%
Gross Margin 83.71% Operating Margin 34.69%
Net Margin 6.91% Free Cash Flow (TTM) 17.82B
ROIC 24.18% FCF Growth (3Y) -10.14%
Safety
Debt / Equity N/A Current Ratio 0.67
Interest Coverage 8.08 Dividend Yield 0.03%
Valuation
P/E Ratio 85.74 P/B Ratio N/A
P/S Ratio 5.92 PEG Ratio -116.18
EV/EBITDA 20.09 Dividend Yield 0.03%
Market Cap 362.35B Enterprise Value 426.19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 61.16B 56.33B 54.32B 58.05B 56.20B
Net Income 4.23B 4.28B 4.86B 11.84B 11.54B
EPS (Diluted) 2.36 2.39 2.72 6.63 6.45
Gross Profit 51.20B 39.43B 33.90B 40.64B 38.75B
Operating Income 21.21B 9.14B 12.76B 18.12B 17.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 133.96B 135.16B 134.71B 138.81B 146.53B
Total Liabilities 137.19B 131.80B 124.31B 121.52B 131.09B
Shareholders' Equity -3.27B 3.33B 10.36B 17.25B 15.41B
Total Debt 69.07B 67.84B 60.12B 64.19B 77.58B
Cash & Equivalents 5.23B 5.52B 12.81B 9.20B 9.75B
Current Assets 29.06B 25.58B 33.00B 28.46B 27.93B
Current Liabilities 43.29B 38.75B 37.84B 29.54B 35.19B